Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Cidara Thera (CDTX)

Cidara Thera (CDTX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
21.54 +0.06 (+0.28%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 21.54 unch (unch) 16:00 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
20.95
Day High
22.06
Open 21.37
Previous Close 21.48 21.48
Volume 50,800 50,800
Avg Vol 166,995 166,995
Stochastic %K 84.47% 84.47%
Weighted Alpha +61.04 +61.04
5-Day Change +2.10 (+10.80%) +2.10 (+10.80%)
52-Week Range 10.14 - 28.42 10.14 - 28.42
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 235,270
  • Shares Outstanding, K 10,953
  • Annual Sales, $ 1,280 K
  • Annual Income, $ -169,830 K
  • EBIT $ -130 M
  • EBITDA $ -130 M
  • 60-Month Beta 0.89
  • Price/Sales 188.13
  • Price/Cash Flow N/A
  • Price/Book 1.47

Options Overview Details

View History
  • Implied Volatility 175.60% ( -5.38%)
  • Historical Volatility 72.57%
  • IV Percentile 93%
  • IV Rank 93.08%
  • IV High 180.98% on 04/23/25
  • IV Low 103.27% on 02/27/25
  • Put/Call Vol Ratio 0.11
  • Today's Volume 30
  • Volume Avg (30-Day) 19
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 396
  • Open Int (30-Day) 294

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -5.45
  • Number of Estimates 1
  • High Estimate -5.45
  • Low Estimate -5.45
  • Prior Year -2.28
  • Growth Rate Est. (year over year) -139.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.22 +41.52%
on 04/07/25
Period Open: 22.03
22.82 -5.61%
on 04/23/25
-0.49 (-2.22%)
since 03/25/25
3-Month
15.22 +41.52%
on 04/07/25
Period Open: 18.91
25.78 -16.44%
on 03/03/25
+2.63 (+13.91%)
since 01/24/25
52-Week
10.14 +112.43%
on 10/15/24
Period Open: 13.00
28.42 -24.21%
on 01/02/25
+8.54 (+65.69%)
since 04/25/24

Most Recent Stories

More News
Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

CDTX : 21.54 (+0.28%)
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX : 21.54 (+0.28%)
PHAT : 4.11 (-0.24%)
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

CDTX : 21.54 (+0.28%)
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

CDTX : 21.54 (+0.28%)
Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response

CDTX : 21.54 (+0.28%)
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025

CDTX : 21.54 (+0.28%)
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology

CDTX : 21.54 (+0.28%)
Cidara Therapeutics: Q4 Earnings Snapshot

Cidara Therapeutics: Q4 Earnings Snapshot

CDTX : 21.54 (+0.28%)
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

CDTX : 21.54 (+0.28%)
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

CDTX : 21.54 (+0.28%)

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company...

See More

Key Turning Points

3rd Resistance Point 23.19
2nd Resistance Point 22.63
1st Resistance Point 22.08
Last Price 21.54
1st Support Level 20.97
2nd Support Level 20.41
3rd Support Level 19.86

See More

52-Week High 28.42
Last Price 21.54
Fibonacci 61.8% 21.44
Fibonacci 50% 19.28
Fibonacci 38.2% 17.12
52-Week Low 10.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective